- Home
- AFJK vs HOWL Comparison
AFJK vs HOWL Comparison
Compare AFJK & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AFJK
- HOWL
- Stock Information
- Founded
- AFJK 2023
- HOWL 2017
- Country
- AFJK United States
- HOWL United States
- Employees
- AFJK N/A
- HOWL N/A
- Industry
- AFJK
- HOWL Biotechnology: Pharmaceutical Preparations
- Sector
- AFJK
- HOWL Health Care
- Exchange
- AFJK NYSE
- HOWL Nasdaq
- Market Cap
- AFJK 95.5M
- HOWL 87.4M
- IPO Year
- AFJK 2023
- HOWL 2021
- Fundamental
- Price
- AFJK $10.60
- HOWL $1.93
- Analyst Decision
- AFJK
- HOWL Strong Buy
- Analyst Count
- AFJK 0
- HOWL 2
- Target Price
- AFJK N/A
- HOWL $13.50
- AVG Volume (30 Days)
- AFJK 5.9K
- HOWL 1.7M
- Earning Date
- AFJK 01-01-0001
- HOWL 11-07-2024
- Dividend Yield
- AFJK N/A
- HOWL N/A
- EPS Growth
- AFJK N/A
- HOWL N/A
- EPS
- AFJK 0.27
- HOWL N/A
- Revenue
- AFJK N/A
- HOWL $3,386,000.00
- Revenue This Year
- AFJK N/A
- HOWL N/A
- Revenue Next Year
- AFJK N/A
- HOWL $191.98
- P/E Ratio
- AFJK $40.08
- HOWL N/A
- Revenue Growth
- AFJK N/A
- HOWL N/A
- 52 Week Low
- AFJK $10.15
- HOWL $1.66
- 52 Week High
- AFJK $10.65
- HOWL $8.19
- Technical
- Relative Strength Index (RSI)
- AFJK N/A
- HOWL 38.11
- Support Level
- AFJK N/A
- HOWL $2.19
- Resistance Level
- AFJK N/A
- HOWL $2.24
- Average True Range (ATR)
- AFJK 0.00
- HOWL 0.20
- MACD
- AFJK 0.00
- HOWL -0.09
- Stochastic Oscillator
- AFJK 0.00
- HOWL 1.65
About AFJK AIMEI HEALTH TECHNOLOGY CO LTD
Aimei Health Technology Co Ltd is a blank check company.
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.